Other HIV Vaccine Trials

The following is a list of HIV vaccine trials being conducted in various phases for infected and non-infected individuals.

Current Therapeutic HIV Vaccine Trials

Phase III

  1. A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of 141W94 Plus Current Nucleoside Therapy versus Current Nucleoside Therapy Alone in Protease-Naïve HIV-Infected Children.

Phase I

  1. A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers.
  2. A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects.
  3. Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection.

 

Current Preventive HIV Vaccine Trials

Phase III

  1. A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-Infection in North America.

 

Phase II

  1. A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers.

Phase I/II

  1. A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects.
  2. Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAX B/B and B/E Vaccines in the United States.

Phase I

  1. A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults.
  2. A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers.
  3. GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers.
  4. GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular of Intradermal Administration in HIV Seronegative Volunteers.
  5. Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers.
  6. A Phase I, Multicenter, Randomized, Double-Blind, Placebo Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination with QS21 Adjuvant or Alum in Healthy Adults.
  7. A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed with Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults.
  8. A Phase I Trial to Compare the Safety and Immunogenicity of the Live Recombinant Canarypox ALVAC-HIV Vaccines, VCP205, VCP1433, and VCP1452, in HIV-1 Uninfected Adult Volunteers.
  9. A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers.
  10. A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers.
  11. Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules.
  12. A Phase I Safety and Immunogenicity Trial of Orally Administered Live Attenuated Recombinant Salmonella typhi CVD 908 delta-asd (pW57-asd+) Expressing HIV-1 LAI gp120 (VVG 203) and Parenterally Administered HIV-1 SF-2 RGP120 in MF59 in HIV-1-Uninfected Volunteers.
  13. A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed with Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults.

 

Current HIV Clinical Trials in Unspecified Phases

  1. Prediction of Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Possible Synthetic Vaccines.
  2. An Expanded Access Open Label Protocol of Remune (HIV-Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /ml and Greater.

3. An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV- 1-Infected Adults With CD4 Count Less Than 300 cells/ml.

4. A Study to Investigate the Potential of Thalidomide Treatment to Enhance Immune Responses in HIV-Infected Individuals Who Are Receiving Highly Active Antiretroviral Therapy.

For questions or comments with regard to the contents of this page please contact Erin_Kil@brown.edu

References:

"General Vaccine Information", AIDS Clinical Trials Information Service. (1999)

http://www.actis.org/actis.asp?URL=vaccine&VIEW=general

Back to Vaccine Strategies

Back to HIV